The oral poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib ( Talzenna – Pfizer) has been approved by the FDA for use in combination with the androgen receptor blocker enzalutamide (Xtandi) for…
Med Lett Drugs Ther. 2023 Aug 7; 65(1682):e134-5 doi:10.58347/tml.2023.1682e
The oral poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib ( Talzenna – Pfizer) has been approved by the FDA for use in combination with the androgen receptor blocker enzalutamide (Xtandi) for treatment of adults with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). The drug has been available since 2018 for treatment of deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer.
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib ( Lynparza – AstraZeneca) has now been approved by the FDA for use in combination with abiraterone ( Zytiga , and others) and either prednisone…
Med Lett Drugs Ther. 2023 Jun 26; 65(1679):e106-7 doi:10.58347/tml.2023.1679g
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib ( Lynparza – AstraZeneca) has now been approved by the FDA for use in combination with abiraterone ( Zytiga , and others) and either prednisone or prednisolone for treatment of adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib was previously approved by the FDA for treatment of adults with deleterious or suspected deleterious germline or somatic homologous recombinant repair (HRR) genemutated mCRPC who progressed on prior treatment with enzalutamide (Xtandi) or abiraterone.
The FDA has approved darolutamide ( Nubeqa – Bayer), an androgen receptor inhibitor, for oral treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Darolutamide is the third androgen…
Med Lett Drugs Ther. 2019 Dec 16; 61(1587):201-2
The FDA has approved darolutamide ( Nubeqa – Bayer), an androgen receptor inhibitor, for oral treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Darolutamide is the third androgen receptor inhibitor to be approved for this indication; apalutamide (Erleada) and enzalutamide (Xtandi) , which are also approved for use in patients with metastatic castration-resistant prostate cancer (mCRPC), were approved earlier.
Apalutamide ( Erleada – Janssen) has received accelerated approval from the FDA for treatment of nonmetastatic castration-resistant prostate cancer. It is the first drug to be approved in the US for this…
Med Lett Drugs Ther. 2018 Jul 16; 60(1551):e124-5
Apalutamide ( Erleada – Janssen) has received accelerated approval from the FDA for treatment of nonmetastatic castration-resistant prostate cancer. It is the first drug to be approved in the US for this indication. Apalutamide is an oral antiandrogen that binds to the ligand-binding domain of the androgen receptor.
Radium Ra 223 dichloride ( Xofigo – Bayer), a radiotherapeutic drug, has been approved by the FDA for intravenous treatment of castration-resistant prostate cancer with symptomatic bone metastases and no…
Med Lett Drugs Ther. 2013 Sep 30; 55(1426):79-80
Radium Ra 223 dichloride ( Xofigo – Bayer), a radiotherapeutic drug, has been approved by the FDA for intravenous treatment of castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.
The FDA has approved enzalutamide (en za loo’ ta mide; Xtandi – Astellas/Medivation) for oral treatment of metastatic castration-resistant prostate cancer in patients previously treated with docetaxel (…
Med Lett Drugs Ther. 2013 Mar 4; 55(1411):20
The FDA has approved enzalutamide (en za loo’ ta mide; Xtandi – Astellas/Medivation) for oral treatment of metastatic castration-resistant prostate cancer in patients previously treated with docetaxel ( Taxotere , and generics). It is the second oral drug approved for this indication; abiraterone acetate (Zytiga) , which is also approved for first-line use, was the first. Cabazitaxel (Jevtana) , which is given parenterally, has a similar indication.